文献速递功能神经外科神经重症

经皮球囊压迫术通过神经炎症与神经递质调节对三叉神经痛发挥多维疗效

Percutaneous Balloon Compression Exerts Multidimensional Efficacy in Trigeminal Neuralgia via Neuroinflammation and Neurotransmitter Regulation.
PubMed 文献 · World Neurosurg · 2025-12-01

真实世界研究纳入140例三叉神经痛患者(68例PBC vs 72例药物治疗),经倾向性评分匹配得57对。PBC组VAS降幅、抑郁焦虑改善及SF-36增益均优于对照组(P<0.05),5-羟色胺、P物质、IL-1β、TNF-α显著下降,总有效率98.08% vs 84.62%且并发症更低。

要点

  • PBC除镇痛外可改善三叉神经痛患者抑郁焦虑及生活质量。
  • PBC降低血清5-羟色胺、P物质、IL-1β及TNF-α水平。
  • PBC干预、VAS降幅及细胞因子调节为疗效独立预测因素。

核心结论

  • PBC除镇痛外可减轻三叉神经痛患者情感障碍并调节神经炎症信号。
  • PBC对疼痛-神经免疫轴的调节支持神经精神整合管理策略。

研究设计与样本

  • 真实世界回顾性分析纳入140例三叉神经痛患者,68例PBC vs 72例药物治疗对照。
  • 经倾向性评分匹配形成57对匹配队列。

主要发现

  • PBC组VAS降幅优于对照(净DID:-0.97;95%CI:-1.41至-0.53;P<0.05)。
  • PBC组汉密尔顿抑郁/焦虑量表及SF-36改善优于对照(DID:+2.03;P<0.05)。
  • PBC组5-羟色胺、P物质、IL-1β及TNF-α显著下降(DID交互P<0.01)。
  • PBC总有效率98.08% vs 84.62%,并发症更低。
  • GEE确认PBC干预(β=3.21,P=0.002)、VAS降幅(βVAS_diff=-1.21,P=0.003)及细胞因子调节为疗效独立预测因素。

关键数值与推荐

  • PBC组VAS净DID为-0.97(95%CI:-1.41至-0.53),P<0.05。
  • SF-36增益DID为+2.03,P<0.05。
  • PBC干预β=3.21,P=0.002;VAS降幅β=-1.21,P=0.003。
  • 总有效率PBC组98.08% vs 对照组84.62%。

临床怎么用

  • PBC可作为三叉神经痛兼具镇痛与改善情感障碍及生活质量的干预选择。
  • 围术期可关注血清5-羟色胺、P物质、IL-1β及TNF-α变化以评估神经炎症调节。
  • 对合并抑郁焦虑的三叉神经痛患者可考虑PBC并联合神经精神管理。

局限性

  • 为单中心回顾性真实世界研究,样本量140例,匹配后57对。
  • 原文未报告随访时长及盲法设置。
  • 血清生物标志物与临床结局的因果关联需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This real-world study evaluated the multidimensional efficacy of percutaneous balloon compression (PBC) in trigeminal neuralgia (TN), focusing on pain relief, psychological comorbidities, quality of life, and neuroinflammation modulation. METHODS: A retrospective analysis included 140 TN patients (68 PBC vs. 72 pharmacotherapy controls), with 57 propensity score-matched pairs. Outcomes comprised visual analog scale (VAS), Hamilton Depression/Anxiety Scales, Short Form-36 Health Survey quality of life scores, and serum biomarkers (5-hydroxytryptamine, Substance P, interleukin 1β, and tumor necrosis factor-alpha). Difference-in-differences (DID) models quantified net treatment effects; generalized estimating equations identified predictors of efficacy. RESULTS: PBC demonstrated superior outcomes versus controls (all P < 0.05): greater VAS reduction (net DID: -0.97; 95% confidence interval: -1.41 to -0.53), Hamilton Depression Scale/Hamilton Anxiety Scale improvements, and Short Form-36 Health Survey gains (DID: +2.03). Biomarker analysis revealed significant declines in PBC-treated patients for 5-hydroxytryptamine, Substance P, interleukin 1β, and tumor necrosis factor-alpha (DID interactions P < 0.01). Total efficacy was higher with PBC (98.08% vs. 84.62%) with lower complications. Generalized estimating equation confirmed PBC intervention (β = 3.21, P = 0.002), pain reduction (βVAS_diff = -1.21, P = 0.003), and cytokine modulation as independent predictors of efficacy. CONCLUSIONS: Beyond analgesia, PBC attenuates affective disorders and normalizes neuroinflammatory signaling in TN. Its modulation of the pain-neuroimmune axis supports integrated neuropsychiatric management strategies.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Du Y, Shi H, Xi Z, et al. Percutaneous Balloon Compression Exerts Multidimensional Efficacy in Trigeminal Neuralgia via Neuroinflammation and Neurotransmitter Regulation. World Neurosurg. 2025. PMID: 41338382. doi:10.1016/j.wneu.2025.124685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。